Akebia Therapeutics (AKBA) EPS (Diluted) Growth (1y) (2018 - 2026)
Akebia Therapeutics (AKBA) EPS (Diluted) Growth (1y) (2018 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EPS (Diluted) Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 44.51 Bn | 43.55 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 43.52 Bn | 39.86 Bn | 2.15 Bn | -304.28% |
| 3 | Zoetis | 32.43 Bn | 30.75 Bn | 1.05 Bn | 1.28% |
| 4 | Takeda Pharmaceutical | 28.63 Bn | 22.83 Bn | 5.10 Bn | -15.70% |
| 5 | United Therapeutics | 21.87 Bn | 19.21 Bn | 683.80 Mn | 13.47% |
| 6 | Viatris | 18.98 Bn | 18.09 Bn | 1.46 Bn | -2,504.14% |
| 7 | Neurocrine Biosciences | 15.43 Bn | 15.04 Bn | 935.80 Mn | 30.20% |
| 8 | Elanco Animal Health | 12.02 Bn | 11.49 Bn | 798.00 Mn | 385.28% |
| 9 | Dr Reddys Laboratories | 10.14 Bn | 9.98 Bn | - | - |
| 10 | Akebia Therapeutics | 244.72 Mn | 89.17 Mn | 38.70 Mn | -3,726.56% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -3,726.56% |
| Mar 31, 2026 | -234.02% |
| Dec 31, 2025 | 55.96% |
| Sep 30, 2025 | 102.07% |
| Jun 30, 2025 | 102.23% |
| Mar 31, 2025 | 128.83% |
| Dec 31, 2024 | -3,400.59% |
| Sep 30, 2024 | -23.81% |
| Jun 30, 2024 | 31.57% |
| Mar 31, 2024 | 39.67% |
| Dec 31, 2023 | 114.52% |
| Sep 30, 2023 | 73.85% |
| Jun 30, 2023 | -138.66% |
| Mar 31, 2023 | 58.87% |
| Dec 31, 2022 | 94.51% |
| Sep 30, 2022 | 14.14% |
| Jun 30, 2022 | 130.05% |
| Mar 31, 2022 | 19.58% |
| Dec 31, 2021 | 35.67% |
| Sep 30, 2021 | 18.10% |